3
3
3
3.82 (t, J 4.7 Hz, 4H, OCH2CH2), 4.03 (t, overlapped, J 6.7
3
4.6 Hz, 4H, OCH2), 6.83 (d, J 8.8 Hz, 4H, H3’,5’), 8.13 (d, J
8.8 Hz, 4H, H2’,6’), 8.36 (s, 4H, H4,6); 13C-NMR (100 MHz,
CDCl3): dC 67.50, 68.45, 69.52, 69.68, 70.78, 70.86, 70.92, 70.96
(OCH2), 114.49 (C-3’,5’), 129.12 (C-2’,6’), 130.27 (C-1’), 144.11
(C-4,6), 151.00 (C-2), 157.98 (C-4’), 160.46 (C-5); EIMS m/z
(relative intensity, %): 692 [M]1 (51), 662 (6), 649 (42), 605 (21),
561 (50), 547 (10), 534 (23), 347 (18), 334 (20), 290 (16), 281
(12), 267 (15), 259 (23), 241 (24), 227 (21), 215 (100), 188 (35),
121 (62), 108 (32); ESI-MS m/z (relative intensity, %): 731 [M 1
K]1 (36), 715 [M 1 Na]1 (81), 693 [M 1 H]1 (100).
3
Hz, 4H, OCH2), 4.07 (t, overlapped, J 4.7 Hz, 4H, OCH2),
6.88 (d, 3J 8.8 Hz, 4H, H3’,5’), 8.22 (d, 3J 8.8 Hz, 4H, H2’,6’), 8.35
(s, 4H, H4,6).
6,9,12,15,18,27,39-Heptaoxa-3,21,47,50-tetraazapentacyclo-
[38.2.2.22,5.219,22.223,26]pentaconta-1(42),2,4,19,21,23,25,40,43,
45,47,49-dodecaene (E). CompoundEwassynthesisedfrom1,11-
bis[4-(5-hydroxypyrimidin-2-yl)phenoxy]undecane 11 (0.3 mmol,
148 mg), 1,11-bis(toluene-4-sulfonyloxy)-3,6,9-trioxaundecane
(0.3 mmol, 150 mg), K2CO3 (3 mmol, 414 mg) and KOTs
(3 mmol, 630 mg) in dry DMF (140 mL) and purified by
chromatography (Chromatotron, CH2Cl2–EtOH ~ 10: 0.5...2)
and repeated crystallisation from heptane to yield 45 mg (22%)
E. Transition temperatures/uC: K 146 (N 145) Iso; HRMS m/z:
C39H50N4O7 requires 687.3757 [M 1 1]1; found 687.3773;
1H-NMR (CDCl3, 500 MHz): dH 1.24–1.34 (m, 10H, CH2),
6,9,12,15,18,27,30,33,36,39-Decaoxa-4,20,48,49-tetraazapenta-
cyclo[38.2.2.22,5.219,22.223,26]pentaconta-1(42),2,4,19,21,23,25,
40,43,45,47,49-dodecaene (B2). Compound B2 was synthesised
from 1,11-bis[5-(4-hydroxyphenyl)pyrimidin-2-yloxy]-3,6,9-trioxa-
undecane 7 (0.082 mmol, 42 mg), 1,11-bis(toluene-4-sulfonyl-
oxy)-3,6,9-trioxaundecane (0.082 mmol, 41 mg), K2CO3 (1 mmol,
138 mg) and KOTs (1 mmol, 210 mg) in dry DMF (70 mL) and
purified by chromatography (Chromatotron, CH2Cl2–EtOH ~
10 : 0.5...2) and repeated crystallisation from toluene–heptane
to yield 9 mg (16%) B2. Transition temperatures/uC: K 131 SmA
175 Iso; HRMS m/z: C36H44N4O10 requires 693.3135 [M 1 1]1;
3
1.40–1.44 (m, 4H, CH2), 1.73 (t, J 6.7 Hz, 4H, OCH2CH2),
3.64–3.66 (m, 4H, OCH2), 3.68–3.71 (m, 4H, OCH2), 3.83 (t, 3J
4.6 Hz, 4H, OCH2CH2), 3.95 (t, 3J 6.7 Hz, 4H, OCH2), 4.17 (t,
3
3J 4.6 Hz, 4H, OCH2), 6.88 (d, J 8.8 Hz, 4H, H3’,5’), 8.21 (d,
3J 8.8 Hz, 4H, H2’,6’), 8.39 (s, 4H, H4,6); 13C-NMR (100 MHz,
CDCl3): dC 25.16, 27.72, 27.99, 28.12, 28.58 (CH2), 67.77,
68.44, 69.54, 70.77, 70.95 (OCH2), 114.51 (C-3’,5’), 129.13
(C-2’,6’), 130.00 (C-1’), 144.26 (C-4,6), 151.01 (C-2), 158.10
(C-4’), 160.87 (C-5); EIMS m/z (relative intensity, %): 686 [M]1
(100), 657 (6), 643 (11), 615 (4), 559 (19), 547 (7), 215 (12), 188
(26), 171 (11); ESI-MS m/z (relative intensity, %): 715 [M 1
K]1 (28), 709 [M 1 Na]1 (29), 693 [M 1 Li]1 (34), 687 [M 1
H]1 (100), 669 (9).
1
found 693.3163; H-NMR (CDCl3, 500 MHz) dH 3.65–3.67 (m,
4H, OCH2), 3.68–3.75 (m, 12H, OCH2), 3.87 (t, J 4.7 Hz, 4H,
3
OCH2CH2), 3.91 (t, 3J 4.9 Hz, 4H, OCH2CH2), 4.04 (t, 3J 4.7 Hz,
4H, OCH2), 4.51 (t, 3J 4.9 Hz, 4H, OCH2), 6.89 (d, 3J 8.6 Hz, 4H,
H3’,5’), 7.22 (d, 3J 8.6 Hz, 4H, H2’,6’), 8.50 (s, 4H, H4,6); 13C-NMR
(100 MHz, CDCl3): dC 67.06, 67.69, 69.24, 69.64, 70.76, 70.85,
70.89, 70.92 (OCH2), 115.42 (C-3’,5’), 127.00 (C-1’), 127.52
(C-2’,6’), 127.78 (C-5), 156.79 (C-4,6), 159.12 (C-4’), 164.37
(C-2); EIMS m/z (relative intensity, %): 692 [M]1 (50), 649 (38),
561 (47), 215 (100), 188 (34), 121 (63).
6,9,12,15,18,21,30,45-Octaoxa-4,23,54,55-tetraazapentacyclo-
[44.2.2.22,5.222,25.226,29]hexapentaconta-1(48),2,4,22,24,26,28,46,
49,51,53,55-dodecaene (G3). Compound G3 was synthesised
from 1,14-bis[5-(4’-hydroxyphenyl)pyrimidin-2-yloxy]-3,6,9,12-
tetraoxatetradecane 8 (0.24 mmol, 141 mg), 1,14-dibromotetra-
decane (0.24 mmol, 86 mg), K2CO3 (3 mmol, 414 mg) and KOTs
(3 mmol, 630 mg) in dry DMF (120 mL) and purified by
chromatography (Chromatotron, CH2Cl2–EtOH ~ 10: 0.5...2)
and repeated crystallisation from heptane to yield 12 mg (6%) G3.
Transition temperatures/uC: K 85 SmA 161 Iso; anal. for
C44H60N4O8?0.5H2O requires: C 67.58, H 7.86, N 7.16; found C
67.88, H 7.81, N 7.02%; 1H-NMR (CDCl3, 400 MHz): dH 1.38–
1.40 (m, 12H, CH2), 1.46–1.50 (m, 4H, CH2), 1.74–1.81 (m, 4H,
CH2), 3.63 (s, 4H, OCH2), 3.63–3.71 (m, 8H, OCH2), 3.91 (t,
3J 5.0 Hz, 4H, OCH2CH2), 3.97 (t, 3J 6.5 Hz, 4H, OCH2), 4.60 (t,
3J 5.0 Hz, 4H, OCH2), 6.96 (d, 3J 7.8 Hz, 4H, H3’,5’), 7.39 (d, 3J
7.8 Hz, 4H, H2’,6’), 8.67 (s, 4H, H4,6).
6,9,12,15,18,27,30,33,36,39-Decaoxa-4,25,45,49-tetraazapenta-
cyclo[38.2.2.22,5.219,22.223,26]pentaconta-1(42),2,4,19,21,23,25,
40,43,45,47,49-dodecaene (C). Compound C was synthesised
from 4-{2-[11-(toluene-4-sulfonyloxy)-3,6,9-trioxaundecan-1-
yloxy]pyrimidin-5-yl}phenol 10 (0.60 mmol, 0.35 g), K2CO3
(3 mmol, 0.41 g) and KOTs (3 mmol, 0.63 g) in dry DMF
(100 mL) and purified by chromatography (Chromatotron,
CH2Cl2–EtOH ~ 10 : 0.5...2) and repeated crystallisation from
CH2Cl2–MeOH and CH2Cl2–EtOH to yield 10.6 mg (5%) C.
Transition temperatures/uC: K 140 SmA 169 Iso; HRMS
m/z: C36H44N4O10 requires 693.3135 [M
693.3105; 1H-NMR (CDCl3, 500 MHz): dH 3.68–3.71 (m,
8H, OCH2), 3.89–3.91 (m, 8H, OCH2), 4.10 (t, J 4.5 Hz, 4H,
1
1]1; found
3
OCH2CH2), 4.47 (m, 4H, OCH2), 6.88 (d, 3J 8.4 Hz, 4H, H3’,5’),
7.24 (covered, 4H, H2’,6’), 8.49 (s, 4H, H4,6); 13C-NMR
(100 MHz, CDCl3): dC 67.14, 67.86, 69.42, 69.68, 70.82,
70.89, 71.08 (OCH2), 115.62 (C-3’,5’), 126.63 (C-1’), 127.53
(C-2’,6’), 128.04 (C-5), 156.88 (C-4,6), 159.28 (C-4’), 164.23
(C-2); EIMS m/z (relative intensity, %): 692 [M]1 (100); ESI-
MS m/z (relative intensity, %): 731 [M 1 K]1 (24), 715 [M 1
Na]1 (36), 693 [M 1 H]1 (100).
Acknowledgements
This work was supported by the Deutsche Forschungsge-
meinschaft (DFG) and the Fonds der Chemischen Industrie.
References
6,18,27,30,33,36,39-Heptaoxa-3,21,47,50-tetraazapentacy-
clo[38.2.2.22,5.219,22.223,26]pentaconta-1(42),2,4,19,21,23,25,40,
43,45,47,49-dodecaene (D). Compound D was synthesised
from 1,11-bis[4-(5-hydroxypyrimidin-2-yl)phenoxy]-3,6,9-trioxa-
undecane 3 (0.3 mmol, 153 mg), 1,11-dibromoundecane
(0.3 mmol, 94 mg), K2CO3 (3 mmol, 414 mg) and KOTs
(3 mmol, 630 mg) in dry DMF (120 mL) and purified by
chromatography (Chromatotron, CH2Cl2–EtOH ~ 10: 0.5...2)
and repeated crystallisation from heptane to yield 54 mg (26%)
D. Transition temperatures/uC: K 131 N 168 Iso; anal. for
C39H50N4O7 requires: C 68.20, H 7.34, N 8.16; found: C 67.82,
1
D. Demus, J. Goodby, G. W. Gray, H.-W. Spiess and V. Vill,
Handbook of Liquid Crystals, Wiley-VCH, Weinheim, 1998.
G. Pelzl, S. Diele and W. Weissflog, Adv. Mater., 1999, 11, 707.
C. Tschierske, Ann. Rep. Progr. Chem. C, 2001, 97, 191.
C. Tschierske, Curr. Opin. Colloid Interface Sci., 2002, 7, 69.
C. T. Imrie, Structure and Bonding 95: Liquid Crystals II, ed.
D. M. P. Mingos, Springer, Berlin, 1999, p. 149.
Selected examples of LC oligomesogens: (a) A. T. M. Marcelis,
A. Koudijs and E. J. R. Sudho¨lter, Mol. Cryst. Liq. Cryst., 1999,
330, 45; (b) S.-M. Huh, J.-I. Jin, M.-F. Achard and F. Hardouin,
Liq. Cryst., 1999, 26, 919; (c) J. Andersch, S. Diele, C. P. Go¨ring,
J.-A. Schro¨ter and C. Tschierske, Chem. Commun., 1995, 107;
(d) R. Lunkwitz, C. Tschierske and S. Diele, J. Mater. Chem.,
1997, 7, 2001; (e) H. Budig, S. Diele, R. Paschke, D. Stro¨hl and
C. Tschierske, J. Chem. Soc., Perkin Trans. 2, 1996, 2, 1901;
(f) T. E. Mann, J. Haley and D. Lacey, J. Mater. Chem., 1999, 9, 353;
2
3
4
5
6
1
H 7.38, N 8.03%; H-NMR (CDCl3, 500 MHz): dH 1.31–1.43
(m, 10H, CH2), 1.45–1.47 (m, 4H, CH2), 1.77 (t, 3J 6.7 Hz, 4H,
OCH2CH2), 3.64–3.67 (m, 4H, OCH2), 3.68 (m, 4H, OCH2),
J. Mater. Chem., 2003, 13, 778–784
783